Loading...
Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.
Conibear, J Chia, B Ngai, Y Bates, A Counsell, N Patel, R Eaton, D Fenwick, J Forster, M
Conibear, J
Chia, B
Ngai, Y
Bates, A
Counsell, N
Patel, R
Eaton, D
Fenwick, J
Forster, M
Citations
Altmetric:
Abstract
Following growing evidence to support the safety, local control (LC) and potential improvement in overall survival (OS) in patients with oligometastatic non-small cell lung cancer (NSCLC) that have been treated with local ablative therapy such as stereotactic ablative radiotherapy (SABR) and stereotactic radiosurgery (SRS), we initiate the SARON trial to investigate the impact and feasibility of adding SABR/SRS and radical radiotherapy (RRT) following standard chemotherapy on OS.
Affiliation
Description
Date
2018-04-17
Publisher
Collections
Files
Keywords
Type
Article
Citation
Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. 2018, 8(4): BMJ Open